Neeraj Agarwal/primeinc.org
Feb 20, 2025, 09:43
Neeraj Agarwal: No OS or PFS benefit with SG in pretreated mUC bladder cancer
Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, shared a post on X about a paper by Tom Powles et al. published in Annals of Oncology:
“Just in Annals of Oncology by Tom Powles, Petros Grivas and team.
Ph3 TROPiCS-04 trial result.
Sacituzumab govitecan (SG) vs physician’s choice chemoRx in pretreated mUC bladder cancer.
No OS or PFS benefit with SG.”
“Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial”
Authors: Tom Powles, Petros Grivas et al.
More posts featuring Neeraj Agarwal.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 26, 2025, 15:47
Mar 26, 2025, 15:07
Mar 26, 2025, 14:53
Mar 26, 2025, 14:43
Mar 26, 2025, 14:26
Mar 26, 2025, 14:11